Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Maintains Target Price $5
Prime Medicine, Inc. (PRME) Gets a Hold From Morgan Stanley
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $7 to $14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Prime Medicine Reports Q3 2024 Financial Progress
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Rozaidi72 : All the analyst giving position comments and hold BUY with target range up to US$7….. but it keeps on sliding…